{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:29:46Z","timestamp":1777307386179,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["116019"],"award-info":[{"award-number":["116019"]}]},{"name":"European Union\u2019s Horizon 2020 Research and Innovation Programme"},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Since the widespread adoption of palivizumab prophylaxis in Europe, there have been a number of clinical practice guidelines (CPGs) published for the prevention of respiratory syncytial virus (RSV) infection in children. The aim of this systematic review was to identify CPGs for the prevention of RSV infection across Europe.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a systematic literature search and contacted European influenza and respiratory virus networks and public health institutions, to identify national CPGs for the prevention of RSV infection. The Reporting Items for practice Guidelines in Healthcare (RIGHT) Statement checklist was applied to extract data and review the quality of reporting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 20 national CPGs were identified, all published between 2000 and 2018. The greatest discrepancy between guidelines was the recommendations for palivizumab prophylaxis for premature infants, with recommendations varying by gestational age. All guidelines recommended or considered the use of palivizumab in infants with bronchopulmonary dysplasia, 85% (n = 17) in children with congenital heart disease (CHD), and 60% (n = 12) in children with severe combined immunodeficiency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We recommend that agencies publishing RSV prevention guidelines adopt the RIGHT reporting requirements when updating these guidelines to improve the presentation of the evidence-base for decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac059","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:13:27Z","timestamp":1645474407000},"page":"S110-S116","source":"Crossref","is-referenced-by-count":30,"title":["A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis"],"prefix":"10.1093","volume":"226","author":[{"given":"Rachel M","family":"Reeves","sequence":"first","affiliation":[{"name":"Centre for Global Health, University of Edinburgh , Edinburgh , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"van Wijhe","sequence":"additional","affiliation":[{"name":"Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut , Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Lehtonen","sequence":"additional","affiliation":[{"name":"Finnish Institute for Health and Welfare , Helsinki , Finland"},{"name":"Turku University Hospital , Turku , Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Stona","sequence":"additional","affiliation":[{"name":"Fondazione Penta for the Treatment and Care of Children with HIV and Related Diseases , Padova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne C","family":"Teirlinck","sequence":"additional","affiliation":[{"name":"National Institute for Public Health and the Environment, Centre for Infectious Disease Control , Bilthoven , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Vazquez Fernandez","sequence":"additional","affiliation":[{"name":"Department of Methods Development and Analytics, Norwegian Institute of Public Health , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health, Nanjing Medical University , Nanjing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Osei-Yeboah","sequence":"additional","affiliation":[{"name":"Centre for Global Health, University of Edinburgh , Edinburgh , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thea K","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut , Copenhagen , Denmark"},{"name":"Department of Clinical Research, Nordsj\u00e6lland Hospital Hilleroed and University of Southern Denmark , Odense , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terho","family":"Heikkinen","sequence":"additional","affiliation":[{"name":"Turku University Hospital , Turku , Finland"},{"name":"Department of Pediatrics, University of Turku , Turku , Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel","family":"van Boven","sequence":"additional","affiliation":[{"name":"National Institute for Public Health and the Environment, Centre for Infectious Disease Control , Bilthoven , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kon","family":"B\u00f8\u00e5s","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Vaccines, Norwegian Institute of Public Health , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Don\u00e0","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department for Women\u2019s and Children\u2019s Health, University of Padua , Padua , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department for Women\u2019s and Children\u2019s Health, University of Padua , Padua , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6169-6262","authenticated-orcid":false,"given":"Harry","family":"Campbell","sequence":"additional","affiliation":[{"name":"Centre for Global Health, University of Edinburgh , Edinburgh , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"RESCEU Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Openshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwicha","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Falsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Molero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Martinon-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terho","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thea K\u00f8lsen","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"van den Berge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Mikolajczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Abram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eskinder","family":"Tafesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Knirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tin Tin","family":"Myint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Gonzalez","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Dieussaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Dermateau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Stoszek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Gallichan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Kieffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Demont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Cheret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Gavart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Aerssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Wyffels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Cleenewerck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"2022081221391234500_jiac059-CIT0001","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"2022081221391234500_jiac059-CIT0002","author":"Public Health England"},{"key":"2022081221391234500_jiac059-CIT0003","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/pch\/8.10.631","article-title":"Use of palivizumab in children with congenital heart disease.","volume":"8","author":"Canadian Paediatric Society.","year":"2003","journal-title":"Paediatr Child Health"},{"key":"2022081221391234500_jiac059-CIT0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1874285801408010071","article-title":"Respiratory syncytial virus infection in high-risk infants\u2014an update on palivizumab prophylaxis.","volume":"8","author":"Resch","year":"2014","journal-title":"Open Microbiol J"},{"key":"2022081221391234500_jiac059-CIT0005","doi-asserted-by":"crossref","first-page":"595768","DOI":"10.1155\/2013\/595768","article-title":"Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.","volume":"2013","author":"Bawage","year":"2013","journal-title":"Adv Virol"},{"key":"2022081221391234500_jiac059-CIT0006","volume-title":"Raccomandazioni sulla profilassi dell\u2019infezione da virus respirato sincizale (VRS) con il palivizumab","author":"Societa Italiana di Neonatologia.","year":"2015"},{"key":"2022081221391234500_jiac059-CIT0007","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.","volume":"102","author":"The IMpact-RSV Study Group.","year":"1998;","journal-title":"Pediatrics"},{"key":"2022081221391234500_jiac059-CIT0008","author":"European Medicines Agency.","year":"2004."},{"key":"2022081221391234500_jiac059-CIT0009","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/archdischild-2013-303764","article-title":"Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.","volume":"99","author":"Murray","year":"2014","journal-title":"Arch Dis Child"},{"key":"2022081221391234500_jiac059-CIT0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/adc.83.2.122","article-title":"Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.","volume":"83","author":"Thomas","year":"2000","journal-title":"Arch Dis Child"},{"key":"2022081221391234500_jiac059-CIT0011","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta15050","article-title":"Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.","volume":"15","author":"Wang","year":"2011","journal-title":"Health Technol Assess"},{"key":"2022081221391234500_jiac059-CIT0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00019053-200725010-00006","article-title":"Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.","volume":"25","author":"Nuijten","year":"2007","journal-title":"PharmacoEcon"},{"key":"2022081221391234500_jiac059-CIT0013","doi-asserted-by":"crossref","first-page":"ofy031","DOI":"10.1093\/ofid\/ofy031","article-title":"Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value.","volume":"5","author":"Olchanski","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2022081221391234500_jiac059-CIT0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/qshc.4.1.55","article-title":"Developing and implementing clinical practice guidelines.","volume":"4","author":"Grimshaw","year":"1995","journal-title":"Qual Health Care"},{"key":"2022081221391234500_jiac059-CIT0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","article-title":"Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines.","volume":"318","author":"Woolf","year":"1999","journal-title":"BMJ"},{"key":"2022081221391234500_jiac059-CIT0016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1748-5908-4-54","article-title":"Why don\u2019t physicians adhere to guideline recommendations in practice? an analysis of barriers among Dutch general practitioners.","volume":"4","author":"Lugtenberg","year":"2009","journal-title":"Implement Sci"},{"key":"2022081221391234500_jiac059-CIT0017","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2022081221391234500_jiac059-CIT0018","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/M16-1565","article-title":"A reporting tool for practice guidelines in health care: the right statement.","volume":"166","author":"Chen","year":"2017","journal-title":"Ann Intern Med"},{"key":"2022081221391234500_jiac059-CIT0019","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00112-008-1722-y","article-title":"Konsensuspapier zur prophylaxe der RSV-infektion mit palivizumab und Post-RSV-atemwegserkrankung.","volume":"156","author":"Austrian Society for Pediatrics and Adolescent Medicine (\u00d6GKJ).","year":"2008","journal-title":"Monatsschr Kinderheilkd"},{"key":"2022081221391234500_jiac059-CIT0020","author":"Haute Autorit\u00e9 de Sant\u00e9.","year":"2017"},{"key":"2022081221391234500_jiac059-CIT0021","author":"Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Infektiologie.","year":"2018"},{"key":"2022081221391234500_jiac059-CIT0022","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13052-015-0203-x","article-title":"Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).","volume":"41","author":"Bollani","year":"2015","journal-title":"Ital J Pediatr"},{"key":"2022081221391234500_jiac059-CIT0023","doi-asserted-by":"crossref","first-page":"199.e1","DOI":"10.1016\/j.anpedi.2014.10.004","article-title":"Actualizaci\u00f3n de las recomendaciones de la Sociedad Espa\u00f1ola de Neonatolog\u00eda para la utilizaci\u00f3n del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial.","volume":"82","author":"Figueras Aloy","year":"2015","journal-title":"An Pediatr (Barc)"},{"key":"2022081221391234500_jiac059-CIT0024","author":"L\u00e4kemedelsverket.","year":"2015"},{"key":"2022081221391234500_jiac059-CIT0025","author":"l\u2019Office","year":"2009"},{"key":"2022081221391234500_jiac059-CIT0026","author":"Nederlandse Vereniging voor Kindergeneeskunde (NVK).","year":"2005"},{"key":"2022081221391234500_jiac059-CIT0027","author":"\u010cesk\u00e1 Neonatologick\u00e1 Spole\u010dnost.","year":"2014"},{"key":"2022081221391234500_jiac059-CIT0028","first-page":"69","article-title":"Proposal for the use of Synagis for the prevention of RSV disease.","volume":"69","author":"Petmezakis","year":"2006","journal-title":"Pediatriki"},{"key":"2022081221391234500_jiac059-CIT0029","author":"Latvijas Neonatologu Biedr\u012bba.","year":"2015"},{"key":"2022081221391234500_jiac059-CIT0030","volume-title":"Guideline for the use of palivizumab (Synagis\u00ae)","author":"Mater","year":"2016"},{"key":"2022081221391234500_jiac059-CIT0031","author":"Hirth"},{"key":"2022081221391234500_jiac059-CIT0032","author":"National Consultant in the Field of Pediatrics\/ National Consultant in the Field of Neonatology.","year":"2000"},{"key":"2022081221391234500_jiac059-CIT0033","volume-title":"Prescri\u00e7\u00e3o de palivizumab para preven\u00e7\u00e3o de infe\u00e7\u00e3o pelo v\u00edrus sincicial respirat\u00f3rio em crian\u00e7as de risco","author":"Departamento da Qualidade na Sa\u00fade.","year":"2015"},{"key":"2022081221391234500_jiac059-CIT0034","author":"Hreb\u00edk","year":"2012"},{"key":"2022081221391234500_jiac059-CIT0035","author":"Nacionalni In\u0161titute za Javno Zdravje.","year":"2017"},{"key":"2022081221391234500_jiac059-CIT0036","volume-title":"Sinagis (palivizumab) guideline","author":"Neonatal","year":"2009"},{"key":"2022081221391234500_jiac059-CIT0037","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","volume":"134","author":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee.","year":"2014","journal-title":"Pediatrics"},{"key":"2022081221391234500_jiac059-CIT0038","author":"Electronic Medicines Compendium.","year":"2017"},{"key":"2022081221391234500_jiac059-CIT0039","author":"Electronic Medicines Compendium."},{"key":"2022081221391234500_jiac059-CIT0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2016.10.074","article-title":"Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience.","volume":"181","author":"Rajah","year":"2017","journal-title":"J Pediatr"},{"key":"2022081221391234500_jiac059-CIT0041","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"2022081221391234500_jiac059-CIT0042","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1542\/peds.2007-0225","article-title":"Decreased incidence of bronchopulmonary dysplasia after early management changes, including surfactant and nasal continuous positive airway pressure treatment at delivery, lowered oxygen saturation goals, and early amino acid administration: a historical cohort study.","volume":"121","author":"Geary","year":"2008","journal-title":"Pediatrics"},{"key":"2022081221391234500_jiac059-CIT0043","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.3346\/jkms.2015.30.S1.S81","article-title":"Recent changes in the incidence of bronchopulmonary dysplasia among very-low-birth-weight infants in Korea.","volume":"30","author":"Jo","year":"2015","journal-title":"J Korean Med Sci"},{"key":"2022081221391234500_jiac059-CIT0044","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/pch\/18.2.86","article-title":"Bronchopulmonary dysplasia\u2014trends over three decades.","volume":"18","author":"Zysman-Colman","year":"2013","journal-title":"Paediatr Child Health"},{"key":"2022081221391234500_jiac059-CIT0045","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.","volume":"4","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2022081221391234500_jiac059-CIT0046","doi-asserted-by":"crossref","first-page":"e1101","DOI":"10.1542\/peds.2014-0077A","article-title":"Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.","volume":"133","author":"McLaurin","year":"2014","journal-title":"Pediatrics"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac059\/43027111\/jiac059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_1\/S110\/45408196\/jiac059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_1\/S110\/45408196\/jiac059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T21:41:24Z","timestamp":1660340484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/Supplement_1\/S110\/6554001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":46,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2022,3,25]]},"published-print":{"date-parts":[[2022,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac059","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,3,25]]}}}